Keywords
type 2 diabetes
biomarkers
glycaemic control
precision medicine
clinical trial
epidemiology
public health
diagnosis
prognosis
randomised controlled trial
cohort study
biomarkers
glycaemic control
precision medicine
clinical trial
epidemiology
public health
diagnosis
prognosis
randomised controlled trial
cohort study
Abstract
Early identification of treatment responders could transform diabetes care. We measured a panel of 24 serum biomarkers in 612 patients initiating second-line therapy and modelled 12-month glycaemic response.
A four-marker signature predicted response with an AUC of 0.83, outperforming baseline HbA1c alone. These findings support biomarker-guided treatment selection in type 2 diabetes.
Downloads
Download data is not yet available.